title: Theranostic applications of antibodies in oncology.
abstract: Targeted therapies, including antibodies, are becoming increasingly important in cancer therapy. Important limitations, however, are that not every patient benefits from a specific antibody therapy and that responses could be short-lived due to acquired resistance. In addition, targeted therapies are quite expensive and are not completely devoid of side-effects. This urges the need for accurate patient selection and response monitoring. An important step towards personalizing antibody treatment could be the implementation of theranostics. Antibody theranostics combine the diagnostic and therapeutic potential of an antibody, thereby selecting those patients who are most likely to benefit from antibody treatment. This review focuses on the clinical application of theranostic antibodies in oncology. It provides detailed information concerning the suitability of antibodies for theranostics, the different types of theranostic tests available and summarizes the efficacy of theranostic antibodies used in current clinical practice. Advanced theranostic applications, including radiolabeled antibodies for non-invasive functional imagining, are also addressed. Finally, we discuss the importance of theranostics in the emerging field of personalized medicine and critically evaluate recent data to determine the best way to apply antibody theranostics in the future.
authors.affiliation: Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands. Electronic address: Emmy.Fleuren@radboudumc.nl.
authors.forename: Emmy D G
authors.initials: ED
authors.lastname: Fleuren
authors.affiliation: Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
authors.forename: Yvonne M H
authors.initials: YM
authors.lastname: Versleijen-Jonkers
authors.affiliation: Department of Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
authors.forename: Sandra
authors.initials: S
authors.lastname: Heskamp
authors.affiliation: Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
authors.forename: Carla M L
authors.initials: CM
authors.lastname: van Herpen
authors.affiliation: Department of Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
authors.forename: Wim J G
authors.initials: WJ
authors.lastname: Oyen
authors.affiliation: Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
authors.forename: Winette T A
authors.initials: WT
authors.lastname: van der Graaf
authors.affiliation: Department of Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
authors.forename: Otto C
authors.initials: OC
authors.lastname: Boerman
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D007159:Immunologic Tests / Q000379:methods; D007167:Immunotherapy / Q000379:methods; D008495:Medical Oncology / Q000379:methods / Q000639:trends; D058990:Molecular Targeted Therapy / Q000379:methods; D009369:Neoplasms / Q000175:diagnosis* / Q000628:therapy*
chemical_list: D000906:Antibodies
keywords: Antibody; Biomarker; Molecular imaging; Personalized medicine; Theranostics
references.citation: Nat Rev Cancer. 2004 Oct;4(10):806-13
references.pmid: 15510161
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7195s-7200s
references.pmid: 16203821
references.citation: Int J Cancer. 2013 Jul 15;133(2):427-36
references.pmid: 23335077
references.citation: Eur J Cancer. 2008 Sep;44(13):1835-40
references.pmid: 18632262
references.citation: Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):194-201
references.pmid: 16111589
references.citation: J Clin Microbiol. 1983 Apr;17(4):655-65
references.pmid: 6343423
references.citation: J Natl Cancer Inst. 1991 Jan 16;83(2):97-104
references.pmid: 1988695
references.citation: World J Gastroenterol. 2013 Oct 7;19(37):6165-9
references.pmid: 24115812
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8646-54
references.pmid: 16314626
references.citation: Eur J Cancer. 2011 May;47(8):1258-66
references.pmid: 21345666
references.citation: J Nucl Med. 2005 Apr;46(4):634-41
references.pmid: 15809486
references.citation: Cancer Discov. 2011 Dec;1(7):573-9
references.pmid: 22389872
references.citation: Blood. 2013 Jun 13;121(24):4854-60
references.pmid: 23591789
references.citation: Annu Rev Biomed Eng. 1999;1:241-63
references.pmid: 11701489
references.citation: J Nucl Med. 2013 Jul;54(7):1014-8
references.pmid: 23651946
references.citation: Hum Antibodies. 2010;19(1):7-13
references.pmid: 20555126
references.citation: Lancet Oncol. 2010 Aug;11(8):753-62
references.pmid: 20619739
references.citation: Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):458-69
references.pmid: 15821965
references.citation: Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1857-67
references.pmid: 18491091
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7454-61
references.pmid: 16243819
references.citation: Clin Cancer Res. 2006 Nov 1;12(21):6326-30
references.pmid: 17085641
references.citation: Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3839S-44S
references.pmid: 14506181
references.citation: J Clin Oncol. 2013 Mar 20;31(9):1157-63
references.pmid: 23382472
references.citation: J Nucl Med. 2003 Feb;44(2):260-8
references.pmid: 12571219
references.citation: J Nucl Med. 2010 Nov;51(11):1707-15
references.pmid: 20956472
references.citation: Am Fam Physician. 2008 Feb 1;77(3):311-9
references.pmid: 18297955
references.citation: Clin Cancer Res. 2012 Jan 1;18(1):40-50
references.pmid: 22215905
references.citation: Gynecol Oncol. 1997 Jun;65(3):425-9
references.pmid: 9190969
references.citation: Clin Cancer Res. 2013 Feb 15;19(4):929-37
references.pmid: 23169435
references.citation: Cancer Biother Radiopharm. 2003 Aug;18(4):513-24
references.pmid: 14503945
references.citation: Curr Hematol Malig Rep. 2012 Mar;7(1):65-73
references.pmid: 22109628
references.citation: Oncogene. 2003 Oct 20;22(47):7359-68
references.pmid: 14576843
references.citation: J Nucl Med. 2009 Jan;50(1):123-31
references.pmid: 19091906
references.citation: Eur J Cancer. 2011 Jul;47(10):1595-602
references.pmid: 21429739
references.citation: Clin Chem. 2000 Aug;46(8 Pt 2):1221-9
references.pmid: 10926916
references.citation: J Nucl Med. 2013 Nov;54(11):1869-75
references.pmid: 24029656
references.citation: J Clin Oncol. 2005 Sep 20;23(27):6540-8
references.pmid: 16170161
references.citation: Eur Urol. 2013 Sep;64(3):478-85
references.pmid: 22980441
references.citation: J Nucl Med. 2009 Aug;50(8):1340-8
references.pmid: 19617342
references.citation: Br J Cancer. 1990 Apr;61(4):538-42
references.pmid: 2139576
references.citation: Eur J Haematol. 2005 Apr;74(4):348-52
references.pmid: 15777348
references.citation: Clin Cancer Res. 2014 Jan 1;20(1):15-20
references.pmid: 24135146
references.citation: Clin Pharmacol Ther. 2010 May;87(5):586-92
references.pmid: 20357763
references.citation: J Clin Oncol. 2006 Sep 20;24(27):4418-25
references.pmid: 16940276
references.citation: J Clin Oncol. 2012 Jun 10;30(17):2119-27
references.pmid: 22565005
references.citation: Clin Cancer Res. 2013 Sep 15;19(18):5182-91
references.pmid: 23714732
references.citation: Cancer Treat Rev. 2013 Oct;39(6):632-9
references.pmid: 23219151
references.citation: J Nucl Med. 2011 Apr;52(4):535-40
references.pmid: 21421715
references.citation: Expert Rev Mol Diagn. 2008 Mar;8(2):141-8
references.pmid: 18366301
references.citation: J Clin Oncol. 2013 Mar 20;31(9):1219-30
references.pmid: 23401453
references.citation: Cancer Chemother Pharmacol. 2013 Apr;71(4):945-53
references.pmid: 23370662
references.citation: J Clin Oncol. 2002 May 15;20(10):2453-63
references.pmid: 12011122
references.citation: Int J Nanomedicine. 2013;8:3703-13
references.pmid: 24124361
references.citation: Clin Cancer Res. 2011 Dec 15;17(24):7693-703
references.pmid: 22038993
references.citation: Curr Mol Med. 2013 Dec;13(10):1506-22
references.pmid: 24206139
references.citation: Mol Imaging Biol. 2009 Jan-Feb;11(1):39-45
references.pmid: 18773247
references.citation: Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):1-7
references.pmid: 18685491
references.citation: J Clin Oncol. 2002 Aug 1;20(15):3262-9
references.pmid: 12149300
references.citation: Med Res Rev. 2014 May;34(3):596-643
references.pmid: 24037872
references.citation: J Clin Oncol. 2006 May 20;24(15):2276-82
references.pmid: 16710024
references.citation: Int J Cancer. 2011 Aug 15;129(4):870-8
references.pmid: 20957635
references.citation: Target Oncol. 2013 Dec;8(4):253-60
references.pmid: 23292309
references.citation: Clin Adv Hematol Oncol. 2006 Mar;4(3):225-31
references.pmid: 16728934
references.citation: J Nucl Med. 2013 Jul;54(7):1045-52
references.pmid: 23572496
references.citation: Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S37-50
references.pmid: 22128287
references.citation: Mol Oncol. 2014 Jun;8(4):799-812
references.pmid: 24725480
references.citation: Nat Rev Cancer. 2012 Mar 22;12(4):278-87
references.pmid: 22437872
references.citation: N Engl J Med. 2012 Nov 8;367(19):1783-91
references.pmid: 23020162
references.citation: Biochemistry. 1996 Mar 5;35(9):2878-84
references.pmid: 8608124
references.citation: J Clin Oncol. 1998 Aug;16(8):2825-33
references.pmid: 9704735
references.citation: Mol Oncol. 2012 Apr;6(2):111-27
references.pmid: 22360993
references.citation: Cancer Res. 2013 Jun 1;73(11):3347-55
references.pmid: 23580572
references.citation: Int J Cancer. 2013 Jul 15;133(2):307-14
references.pmid: 23335047
references.citation: J Histochem Cytochem. 2004 Jul;52(7):893-901
references.pmid: 15208356
references.citation: Biochem Biophys Res Commun. 2009 Dec 4;390(1):48-53
references.pmid: 19769942
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1803-10
references.pmid: 15677699
references.citation: Br J Cancer. 2011 Jan 4;104(1):1-3
references.pmid: 21206496
references.citation: J Cell Physiol. 1993 Nov;157(2):237-42
references.pmid: 7901224
references.citation: Neuro Oncol. 2009 Aug;11(4):423-9
references.pmid: 19060176
references.citation: BMC Cancer. 2013 Feb 22;13:84
references.pmid: 23433435